Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.28 -0.07 (-0.14%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
UK Drug Regulator Warns Of Severe Eye Reactions Associated With Sanofi/Regeneron's Dupixent
Via Benzinga
iPhone Pro Shipments May Miss Consensus, Tesla Rival Charts Ambitious Expansion Plan In Mexico, Amazon Cloud Unit To Add More Employees: Top Stories Wednesday, Nov. 30
Reuters 
Via Benzinga
Horizon Therapeutics Shares Jump On Confirmation Of Takeover Talks With Several Large Companies
Via Benzinga
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
The three companies have until Jan. 10 to decide whether they want to buy Horizon. 
Via Investor's Business Daily
Europe Approves Sanofi's Enjaymo For Rare Form Of Anemia
Via Benzinga
Sanofi (SNY) Q3 2022 Earnings Call Transcript
SNY earnings call for the period ending September 30, 2022. 
Via The Motley Fool
Sanofi Jumps As Strong Third-Quarter Profit Leads To Guidance Boost
Sanofi stock jumped Friday after the company reported better-than-expected profit. 
Via Investor's Business Daily
Dupixent, Flu Vaccine Demand Boost Sanofi's Q3 Earnings, Lifts Annual Outlook
Via Benzinga
First Drug That Can Delay Onset of Type 1 Diabetes Gets FDA Approval After Multiple Regulatory Hurdles
Via Benzinga
Daily Stock Analysis: Sanofi - November 2022 Snapshot
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company's decided in late 2019 to pull back from the cardio-metabolic... 
Via Talk Markets
A Paradigm Shift In Healthcare Produces A Big Market Opportunity
In a couple of years, Dario Heath could easily be a $100M+ company running 60%+ gross margins, be profitable and cash generating. 
Via Talk Markets
Eli Lilly's Twitter Fiasco Continues As Drugmaker Reportedly Pulls 'Millions' In Twitter Ads
The fallout from a fake account continued Monday as Lilly reportedly pulled Twitter ads. 
Via Investor's Business Daily
Can This Company's Research Help Transform Regenerative Medicine As Its Lead Product Receives FDA IND Approval?
Learn More about Organicell Regenerative Medicine, Inc. by gaining access to the latest research report In the medical community, the popularity of regenerative medicine is reportedly soaring primarily... 
Via Benzinga
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each... 
Via Talk Markets
2 Top Biotech Stocks to Buy in November
Both of these companies have potential catalysts on the way. 
Via The Motley Fool
Eli Lilly Dives After Fake Twitter Account Promises Free Insulin; Takes Novo Nordisk, Sanofi With It
A fake, but verified, Twitter account impersonated Eli Lilly and claimed insulin is free. 
Via Investor's Business Daily
Europe Approves Sanofi, GSK's Beta Variant Adapted COVID Shot As Booster
Via Benzinga
Biogen, Seagen Name New CEOs — But One Biotech Stock Crumbles
Biogen jumped after naming Christopher Viehbacher its CEO. David Epstein will take over at Seagen. 
Via Investor's Business Daily
Europe Approves AstraZeneca-Sanofi Partnered Antibody To Prevent RSV Infection In Infants
Via Benzinga
Why Is Provention Biosciences (PRVB) Stock Up 25% Today?
Provention Biosciences shares are trending after reporting earnings. PRVB stock is also up 25% on hopes of FDA approval for teplizumab. 
Via InvestorPlace
Tesla Shifts China Factory Workers To US Plant, Complete European Approval For AstraZeneca's COVID-19 Shot, Tesla Eyes Cybertruck Commercialization From Next Year: Top Stories Tuesday, Nov. 01
Bloomberg Tesla Migrates Shanghai Factory Workers To Boost US Plant Production 
Via Benzinga
Sanofi: Q3 Earnings Insights
Sanofi (NASDAQ:SNY) reported its Q3 earnings results on Friday, October 28, 2022 at 05:00 AM. Here's what investors need to know about the announcement. Earnings Sanofi beat estimated earnings by... 
Via Benzinga
Sanofi's Earnings Outlook
Sanofi (NASDAQ:SNY) is set to give its latest quarterly earnings report on Friday, 2022-10-28. Here's what investors need to know before the announcement. Analysts estimate that Sanofi will report an... 
Via Benzinga
Earnings Scheduled For October 28, 2022
Companies Reporting Before The Bell • TAL Education (NYSE:TAL) is projected to report quarterly earnings at $0.01 per share on revenue of $242.62 million. 
Via Benzinga
3 Dividend Stocks That Could Soar 51% to 58%, According to Wall Street
Two of these three pay especially attractive dividends. 
Via The Motley Fool
US Stock Futures Lower Following Friday's Rally; Tesla In Focus
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Monday after recording sharp gains in the previous session. The Dow Jones jumped by around 750 points on Friday. All the... 
Via Benzinga
New Drugs Approvals Bring No Relief for Ailing Innovent Bio
Key Takeaways: Innovent Bio has brought several drugs to market in recent years, including two announced last week, but is still losing money with no profits in sight The company has overhauled its... 
Via Benzinga
2 High-Yielding Dividend Stocks That Haven't Been This Cheap in Years
Is now the time to buy Sanofi and Intel? 
Via The Motley Fool
3 Red-Hot Stocks That Could Continue to Beat the Market
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
Sanofi - Regeneron Tout Additional Positive Data From Flagship Dupixent Product
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.